Pure Source LLC

DUBLIN, Dec. 14, 2022 /PRNewswire/ -- The "Global Anti TIGIT Antibody Clinical Trials & Companies Insight 2023" report has been added to ResearchAndMarkets.com's offering. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of individual therapies. In addition to other elements, the study includes a detailed assessment of the current market landscape, providing information about the product's mechanism of action, dosage and administration, and other development activities. Report Highlights: Global Anti-TIGIT Antibodies Market Dynamics Insight On Anti TIGIT Antibodies Clinical Trials Insight By Phase, Company, Country, Indication Anti-TIGIT Antibodies In Clinical Trials : > 45 Overview Of Partnerships and Collaborations In The Global Anti-TIGIT Antibodies Market Global Anti-TIGIT Antibodies Market Outlook Competitive Landscape The advancement in the field of genomics has led to the identification of T-cell immunoreceptors with immunoglobulin and ITIM domain (TIGIT) as a promising emerging immune checkpoint target. TIGIT indirectly suppresses T-cell activation and is expressed in multiple types of immune cells, including regulatory T (Treg) cells, activated T cells, and natural killer (NK) cells. TIGIT is upregulated in T cells and NK cells after ligand binding, inhibiting these cells' ability to kill tumor cells. Increased TIGIT expression s also associated with advanced disease and poor survival outcomes. Additionally, increased TIGIT expression after treatment is associated with disease recurrence. Since its identification as a potential immunotherapy target, pharmaceutical companies have developed a robust pipeline of TIGIT inhibitors and are reporting promising preclinical and clinical trial results. Recently, iTeos Therapeutics has announced promising preclinical and clinical analyses supporting the multifaceted mechanism of action of its anti-TIGIT antibody, EOS-448/GSK4428859A, which is being developed in collaboration with GlaxoSmithKline. Various combinations of anti-TIGIT antibody isotopes have been studied in cancer models of mice. Depending on the isotope used, the preclinical analyses of these combinations have demonstrated different anti-tumor activities. Strong anti-tumor activities have been found while using the isotope engaging the Fcandgamma; R, which has been linked to the activation of effector CD8 T cells and the reduction in the number of Treg cells in the tumor microenvironment. EOS-448 has further been shown to induce the depletion of the precursors of exhausted T cells in addition to regulatory T cells, but not of stem-like memory T cells. Recent years have seen an increase in collaborations and partnerships between companies for the faster development of novel drugs. Shanghai Junshi Biosciences and Coherus Bioscience recently announced that the two are taking their immuno-oncology collaboration agreement further by allowing Coherus to initiate its option to license the former's potential anti-TIGIT antibody - JS 006 - in the US and China. Regulatory bodies of the two regions have already approved the drug's Investigational new drug (IND) applications, allowing the companies to develop it further clinically. Apart from this, clinical trials are ongoing which are assessing the drug's safety, pharmacokinetic properties, and tolerability post-dose escalation and expansion, as a monotherapy and in combination with toripalimab, an anti-PD-1 antibody, in patients with advanced solid tumors. Apart from these trends in the market, the pipeline of novel TIGIT inhibitor is highly crowded which suggests a promising future of the market. The key drugs in research and development include including AB 154, Ociperlimab, COM902, EOS448, Tiragolumab, and others. As per our analysis, TIGIT inhibitor is expected to enter the market by 2024, which will transform the overall immunotherapy market during the forecast period. However, the market will mainly be restricted by the long duration of drug development and stringent regulatory guidelines. However, as the healthcare sector of the majority of regions is shifting towards novel therapeutic approaches drug regulatory bodies are providing special provisions and rapid approvals are expected in coming years. As per report findings, the global market is expected to have opportunity of more than US$ 300 Million once the first Anti TIGIT antibody is commercially approved in coming years. The Anti-TIGIT Antibody clinical development and the market opportunity are driven by the rising occurrence of different forms of cancer, technological advancements in the field of immune-oncology for cancer treatment, and rising awareness concerning the benefits of targeted therapies over conventional cancer therapies. Apart from this, rising government initiatives, increasing awareness among the population, and the development of favorable reimbursement policies are also boosting the growth of the market during the forecast period. Key Topics Covered: 1. Introduction to TIGIT Inhibitor 2. Role Of TIGIT Inhibitors By Indications 2.1 TIGIT Inhibitors in Cancer 2.2 TIGIT Inhibitors in HIV 2.3 TIGIT in Autoimmune Disorders 3. Mechanism of Anti TIGIT Antibodies 3.1 Overview 3.2 Clinical Approaches to Target TIGIT 4. Partnerships and Collaborations In The Global Anti TIGIT Antibodies Market 5. Global TIGIT inhibitors Clinical Trials Overview 5.1 By Company 5.2 By Country 5.3 By Indication 5.4 By Patient Segment 6. Global Anti TIGIT Antibody Clinical Pipeline By Company, Indication and Phase 6.1 Research 6.2 Preclinical 6.3 Phase-I 6.4 Phase-I/II 6.5 Phase-II 6.6 Phase-III 7. FDA Orphan Designation for Tiragolumab 8. Global Anti TIGIT Antibody Market Dynamics 8. 1 Market Drivers 8.2 Commercialization Challenges 9. Global TIGIT Inhibitor Market Future Outlook 10. Competitive Landscape 10.1 Arcus Biosciences 10.2 Agenus 10.3 Astellas Pharma 10.4 AstraZeneca 10.5 BeiGene 10.6 Bristol Myers Squibb 10.7 Compugen 10.8 Gilead Sciences 10.9 iTeos Therapeutics 10.10 Merck 10.11 Roche 10.12 Seagen 10.13 Shanghai Henlius Biotech For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Two leading digital health companies partner to offer health systems end-to-end obstetric & postpartum clinical monitoring and patient engagement solution SAN FRANCISCO and CARY, N.C., Dec. 14, 2022 /PRNewswire/ -- Memora Health, the leading intelligent platform for virtual care delivery and complex care management, today announced a partnership with PeriGen, the market leader in applying artificial intelligence (AI) to improve safety in childbirth. The partnership is the first of its kind looking to offer health systems the ability to use advanced technology to monitor and engage obstetrics patients from labor and delivery through the postpartum period at home. This coordinated solution for women's health will be made available to health systems nationally. This is the first collaboration formed to combine a labor and delivery inpatient solution with a post-discharge monitoring tool for those same patients, which have traditionally been separate offerings. Both Memora and PeriGen customers have reported improved outcomes using the respective systems. "Health systems offering robust maternal and fetal monitoring that supports new families during labor and throughout their transition home can gain tremendous lifetime loyalty from these investments," said Manav Sevak, co-founder and CEO of Memora Health. "We're excited to partner with PeriGen to offer this innovative solution that can help health systems continue to use their digital assets as a key strategic lever to remain competitive in a challenging market." "In recent years, the U.S. has witnessed a considerable rise in maternal morbidity and mortality––much of which is preventable," said Matthew Sappern, CEO of PeriGen. "This is a complex, multifactorial challenge and applying technology to standardize and control modifiable factors is an absolute necessity to improvement. Both PeriGen and Memora are expert at this and the combination promises to be powerful." Memora Health delivers AI-backed, evidence-based care programs through dynamic and conversational two-way text to reduce care team burden and improve maternal and infant outcomes. PeriGen's PeriWatch® platform consolidates and summarizes labor and delivery data to promote better human recognition and communication about impending problems during labor. The two companies share a mission to enable clinicians to spend more time on direct patient care and less time in front of screens, to promote the best outcomes for mothers and their babies. About Memora Health Memora Health helps healthcare organizations digitize and automate care programs, making complex care delivery simple for patients and clinicians to navigate. Memora's deep knowledge of clinical workflows and patient experience allows the construction of cohesive digital programs that guide patients through their care episodes, and automates the completion of simple follow-up tasks in the EHR for care teams. Memora's digitized care programs reduce care team notifications by nearly 40%, has an average patient NPS over 70, and improves engagement and clinical outcomes across diverse populations. Memora Health is headquartered in San Francisco, CA, with clients and team members around the world. For more information about Memora Health, visit memorahealth.com. About PeriGen PeriGen Inc., a Halma company, offers innovative perinatal software solutions that incorporate advanced statistical analysis features to enhance clinical efficiency and standardization of care during childbirth. Led by skilled OB practitioners and IT visionaries, PeriGen has created the PeriWatch® platform to provide consistent analysis and efficient display of complex data to promote better human recognition and communication about impending problems during labor. With PeriWatch®, clinicians can spend more time on direct patient care and less time on manual calculations and data manipulation. To learn more, visit ; visit us on Twitter, LinkedIn, YouTube, and Facebook; or email [email protected]. Media Contact: Lara Key, [email protected] SOURCE Memora Health

Findings Part of Five-Year Research Collaboration Between Valo and FDA Developed on Valo's Biowire Platform BOSTON, Dec. 14, 2022 /PRNewswire/ -- Valo Health, Inc ("Valo") shared the initial results of a collaborative study with the U.S. Food and Drug Administration (FDA), demonstrating the potential of Valo's Biowire platform to predict clinical efficacy of Cardiac Contractility Modulation devices to treat heart failure. The study, which is part of a five-year research collaboration between Valo and the FDA was published by the research team in a recent issue of Frontiers in Physiology. The FDA is working to understand how Valo's Biowire platform could be leveraged to evaluate current and future Cardiac Contractility Modulation (CCM) medical devices for the treatment of heart failure patients. The Biowire platform offers an attractive alternative particularly to animal testing by recreating functional adult human heart muscle in vitro, leveraging advances in stem cell technology and tissue engineering. At Valo, these in vitro human tissues are currently being used to accelerate drug discovery efforts. "Through advances in stem cell technology and human tissue engineering Valo's Biowire platform is currently used as a translational tool to accelerate drug discovery efforts," said Michael P. Graziano, Head of Discovery and Translational Biology at Valo. "We are thrilled to extend the use of Valo's Biowire platform through our collaboration to potentially help the FDA assess the safety and efficacy of medical devices; with the ultimate goal of helping to save lives," added Graziano. While previous studies have provided important insights into the understanding of CCM, a major hindrance to the detailed study has been the lack of appropriate in vitro human cardiac models. Lack of human nonclinical models to evaluate cardiac medical device safety and effectiveness currently hinders the regulatory review process and produces a significant burden on animal models. Valo's Biowire platform offers an in vitro model that recapitulates clinical CCM response and may provide mechanistic insights that make it possible to predict which parameters and patient populations will respond to CCM therapy. In the research paper, which was featured in Frontiers in Physiology, the data show that applying CCM pulses to 3D Biowire tissues results in a robust increase in cardiac contractility, mirroring the effect seen clinically in heart failure patients. Conversely, applying the same pulses to the same cardiac cells cultured in 2D on traditional hard substrates, no change in contractility was observed. Valo's functionally mature cardiac tissues provide a physiologically relevant response to the CCM stimulation ranges being used in clinical protocols. The data confirm that 3D models are ideal surrogates when human testing is not possible and animal models are insufficient. This novel in vitro human model opens the door to investigating the mechanism and provides the ability to validate the safety parameters of CCM therapy pre-clinically. This project provides additional data to support the evaluation of in vitro tools that can potentially be used to bring safe and effective new medical devices to patients faster. and may be used to inform the development of standards and FDA guidance. About Valo Health Valo Health, Inc ("Valo") is a technology company built to transform the drug discovery and development process using human-centric data and artificial intelligence driven computation. As a digitally native company, Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company's Opal Computational Platform™ is an integrated set of capabilities designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs across cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, New York, NY, and San Francisco, CA. To learn more, visit . Contacts: Media: Jennifer Hanley, Chief Communications Officer [email protected] Investors: Graeme Bell, Chief Financial Officer [email protected] valohealth. com SOURCE Valo Health LLC